MDC Press Release | Muscular Dystrophy Canada calls on provincial governments to prioritize persons affected by neuromuscular disorders for COVID-19 vaccine
Muscular Dystrophy Canada (MDC) have released a statement regarding Canada’s vaccine roll-out plan and the neuromuscular community. MDC advocates that provincial governments prioritize people living with hereditary and acquired neuromuscular disorders in their vaccination roll-out.
February 23, 2021 – Many people living with neuromuscular disorders (NMD) are at greater risk of developing serious symptoms and complications as a result of COVID-19 due to their often pre-existing cardiac and respiratory issues and chronic comorbidities. As the voice of the NMD community in Canada, Muscular Dystrophy Canada (MDC) is calling on governments to prioritize people living with hereditary and acquired neuromuscular disorders in their vaccination roll-out.
“We want governments to recognize the critical need of the NMD community, to ensure that persons with NMDs are specifically noted as high-risk in roll out plans and prioritize their health, just as we do.”
Stacey Lintern, CEO, Muscular Dystrophy Canada.
Read the Full Release Here
Read next...
Call for Applications: Join the NMD4C Basic Science Trainee Committee (BSTC)
We are now accepting applications from graduate students, research trainees, and postdoctoral fellows working in neuromuscular labs in Canada.
Basic Science Trainee Committee Launches Pre-Clinical Science Standard Operating Procedures
We’re pleased to announce the launch of the BSTC Standard Operating Procedures (SOPs), now available through the NMD4C Resource Hub. These SOPs provide standardized guidance for laboratories, clinics, and research programs across Canada, supporting consistent, high-quality neuromuscular care and research. Explore the full SOP Library and other open-access resources designed to advance collaboration and strengthen practices nationwide.
